Women & HIV
In this presentation Dr. Annemiek de Ruiter, Senior Global Medical Director with ViiV Healthcare, highlights a number of relevant clinical and psychosocial aspects faced by women living with HIV and Healthcare Professionals that manager their health.
Presented by Dr. Annemiek de Ruiter, Senior Global Medical Director, ViiV Healthcare.
TRIUMEQ ▼ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.
Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.
TIVICAY ▼ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children aged 6 years and over, weighing at least 15kg.
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the ViiV Healthcare group of companies.
